ERLONAT 100MG
DESCRIPTION
Erlonat 100mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 100mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.Erlonat 100mg tablets are prescription medicine, Erlonat 100mg tabletused only by the patients who have valid prescription
 |
| ERLONAT 100MG |
INDICATION AND USAGE
Erlonat 100mg is primarily indicated for; Non small cell lung cancer: Erlonat 100mg is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat 100mg is involved in Erlonat 100mg tablet the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlonat 100mg tablet is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat 100mg tablet is used in combination with gemcitabine. In this condition Erlonat 100mg is involved as first line treatment.
WARNING
Some of the adverse Erlonat 100mg tablet effects occur while treating with Erlonat 100mg tablets; Interstitial lung disease Renal impairment Hepatic toxicity Erlonat 100mg tablet with liver failure Gastrointestinal perforation Bullous & Erlonat 100mg tablet exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular disorders Embryo fetal toxicityERLONAT PHARMACOLOGY
Erlonat 100mg tablet has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal Erlonat 100mg tablet growth factor Erlonat 100mg tablet receptor. This EGFR is Erlonat 100mg tablet occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.ERLONAT ADME PROPERTY
ABSORPTION
The peak Erlonat 100mg tablet plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its Erlonat 100mg tablet bioavailability to 100%. The Erlonat 100mg tablet Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlonat 100mg tablet , causes decreasing the exposure of Erlotinib.DISTRIBUTION
Volume of distribution Erlonat 100mg tablet of Erlotinib is 232L Human protein binding to Erlotinib 100mg tablet is occurs as 93%.METABOLISM
The metabolism of Erlotinib 100mg is occurs by CYP3A4ELIMINATION
The route of elimination of Erlotinib 100mgmetabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.
PRODUCT DETAILS
Brand : ErlonatIngredients : Erlotinib
Strength : 100mg
Manufactured : Natco
Package : 30 Tablets
DOSAGE ADMINISTRATION
DOSAGE MANAGEMENT
In NSCLC: The recommended dosage is Erlonat 100mg tablet 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat 100mg is 100mg should be taken Erlonat 100mg tablet as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Erlonat 100mg Interstitial lung disease, pulmonary failure: Discontinue the Erlonat 100mg therapy In severe hepatic failure: Stop the therapy permanentlyIn renal impairment: Discontinue the Erlonat 100mg therapy permanently In gastrointestinal perforation and severe diarrhea: Erlonat 100mg tablet Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive Erlonat 100mg tablet measures In corneal perforation, therapy should be Erlonat 100mg tablet discontinuing permanently. Avoid concomitant use of Erlonat 100mg tablet with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.
